Theralase Technologies Inc. V.TLT

Merck could use some help

[O12009]

• Merck & Co.’s drug Keytruda failed to help people with cancer in two clinical trials, both using the immunotherapy as an add-on to other types of treatment for early-stage lung and skin cancer, the comapny said Thursday.
• Both trials were stopped early following the recommendation of independent data analysts, who said the addition of Keytruda to standard treatments didn’t appear likely to improve survival for study volunteers.
• The study setbacks are a blow to Merck’s plans to further expand Keytruda’s use ahead of an expected patent expiration in 2028. The drugmaker has spent $46 billion developing Keytruda in more than a decade and plans to spend $20 billion more by 2030, CEO Robert Davis said at this year’s American Society of Clinical Oncology annual meeting.

[O12009]

 Keytruda has been Merck’s can’t-miss drug, rapidly becoming one of the best-selling pharmaceutical products of all time with $14 billion in sales in the first six months of 2024 alone. Skin cancer was its first approval and lung cancer has driven a large part of its growth, although it has gained approval in well over a dozen types of cancer. In recent years, however, its expansion into

[CancerSlayer]

As stated per Medical News Today: Keytruda for lung cancer The FDA has approved Keytruda to treat a form of lung cancer called non-small cell lung cancer (NSCLC) in adults. For this use, Keytruda may be prescribed with other drugs or by itself, depending on the type of NSCLC being treated. Keytruda in combination with other lung cancer drugs Keytruda is approved as a

[Alamir1111]

Merck could do a deal today for peanuts  what's the holdup???

[patience69]

Alamir.  No doubt you are correct about that. The problem would be just how many peanuts will it take to make it work 

[Alamir1111]

Me personally  taking a gamble and not a representative of any big pharma  . I would say  low balling  around 3x of today valuation